{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:33:44Z","timestamp":1789122824539,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000886","name":"Duke Endowment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Medication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD initiation and a harm reduction philosophy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate whether low barrier MOUD improved retention in care compared to traditional treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design and participants<\/jats:title>\n                <jats:p>Retrospective cohort study of patients with at least one visit seeking MOUD at the FQHC during a historical control period (3\/1\/2018\u20143\/31\/2019) and a low barrier intervention period (11\/1\/2019\u20147\/31\/2020).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main measures<\/jats:title>\n                <jats:p>Primary outcomes were any MOUD prescription within 6\u00a0months of the index visit and 3- and 6-month retention in treatment without care gap, with care gap defined as 60 consecutive days without a visit or prescription. Secondary outcomes were all-cause hospitalization and emergency department visit within 6\u00a0months of the index visit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key results<\/jats:title>\n                <jats:p>Baseline characteristics were similar between the intervention (n\u2009=\u2009113) and control (n\u2009=\u200990) groups, except the intervention group had higher rates of uninsured, public insurance and diabetes. Any MOUD prescription within 6\u00a0months of index visit was higher in the intervention group (97.3% vs 70%), with higher adjusted odds of MOUD prescription (OR\u2009=\u20094.01, 95% CI 2.08\u20137.71). Retention in care was similar between groups at 3\u00a0months (61.9% vs 60%, aOR\u2009=\u20091.06, 95% CI 0.78\u20131.44). At 6\u00a0months, a higher proportion of the intervention group was retained in care, but the difference was not statistically significant (53.1% vs 45.6%, aOR 1.27, 95% CI 0.93\u20131.73). There was no significant difference in adjusted odds of 6-month hospitalization or ED visit between groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Low barrier MOUD engaged a higher risk population and did not result in any statistically significant difference in retention in care compared with a historical control. Future research should determine what interventions improve retention of patients engaged through low barrier care. Primary care clinics can implement low barrier treatment to make MOUD accessible to a broader population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00342-1","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T06:02:31Z","timestamp":1667628151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-0211","authenticated-orcid":false,"given":"Jamie","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjan","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Poley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Carolyn","family":"Crowder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Feigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"342_CR1","unstructured":"National Institute on Drug Abuse. Overdose Death Rates. National Institute on Drug Abuse. Published January 29, 2021. https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics\/overdose-death-rates Accessed 28 Feb, 2021."},{"key":"342_CR2","unstructured":"Ahmad F, Rossen L, Sutton P. Provisional drug overdose death counts. National center for health statistics. Published December 7, 2021. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm Accessed 28 Feb 2021."},{"key":"342_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357: j1550. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ"},{"key":"342_CR4","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences E and Medicine. Medications for opioid use disorder save lives. The national academies press; https:\/\/doi.org\/10.17226\/25310. 2019","DOI":"10.17226\/25310"},{"key":"342_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","volume":"169","author":"LT Wu","year":"2016","unstructured":"Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117\u201327. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.10.015.","journal-title":"Drug Alcohol Depend"},{"key":"342_CR6","doi-asserted-by":"publisher","unstructured":"Williams A, Nunes E, Olfson M. To Battle The Opioid Overdose Epidemic, Deploy The \u2018Cascade of Care\u2019 Model | Health Affairs. Health Affairs Blog. https:\/\/www.healthaffairs.org\/do\/https:\/\/doi.org\/10.1377\/forefront.20170313.059163\/full\/ Accessed 28 Feb 2021.","DOI":"10.1377\/forefront.20170313.059163\/full"},{"issue":"6","key":"342_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","volume":"19","author":"A Sharma","year":"2017","unstructured":"Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O\u2019Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19(6):35. https:\/\/doi.org\/10.1007\/s11920-017-0783-9.","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"342_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17352\/2455-3484.000008","volume":"1","author":"LG Duncan","year":"2015","unstructured":"Duncan LG, Mendoza S, Hansen H. Buprenorphine maintenance for opioid dependence in public sector healthcare: benefits and barriers. J Addict Med Ther Sci. 2015;1(2):31\u20136. https:\/\/doi.org\/10.17352\/2455-3484.000008.","journal-title":"J Addict Med Ther Sci"},{"issue":"5","key":"342_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","volume":"13","author":"EM Oliva","year":"2011","unstructured":"Oliva EM, Maisel NC, Gordon AJ, Harris AHS. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374\u201381. https:\/\/doi.org\/10.1007\/s11920-011-0222-2.","journal-title":"Curr Psychiatry Rep"},{"issue":"Suppl 3","key":"342_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","volume":"35","author":"K Mackey","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(Suppl 3):954\u201363. https:\/\/doi.org\/10.1007\/s11606-020-06257-4.","journal-title":"J Gen Intern Med"},{"key":"342_CR11","unstructured":"Meges D, Zevin B, Cookson E, et al. Adapting Your Practice: Recommendations for the Care of Homeless Patients with Opioid Use Disorders. Healthcare for the Homeless Clinicians\u2019 Network; 2014. https:\/\/nhchc.org\/wp-content\/uploads\/2019\/08\/hch-opioid-use-disorders_adapting-your-practice-final-to-post.pdf Accessed 28 Feb 2021."},{"issue":"1","key":"342_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/1472-6963-12-222","volume":"12","author":"R Canavan","year":"2012","unstructured":"Canavan R, Barry MM, Matanov A, et al. Service provision and barriers to care for homeless people with mental health problems across 14 European capital cities. BMC Health Serv Res. 2012;12(1):222. https:\/\/doi.org\/10.1186\/1472-6963-12-222.","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"342_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00127-012-0649-8","volume":"48","author":"RM Krausz","year":"2013","unstructured":"Krausz RM, Clarkson AF, Strehlau V, Torchalla I, Li K, Schuetz CG. Mental disorder, service use, and barriers to care among 500 homeless people in 3 different urban settings. Soc Psychiatry Psychiatr Epidemiol. 2013;48(8):1235\u201343. https:\/\/doi.org\/10.1007\/s00127-012-0649-8.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"9","key":"342_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race\/ethnicity and payment. JAMA Psychiat. 2019;76(9):979\u201381. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0876.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"342_CR15","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.drugpo.2013.05.005","volume":"24","author":"C Strike","year":"2013","unstructured":"Strike C, Millson M, Hopkins S, Smith C. What is low threshold methadone maintenance treatment? Int J Drug Policy. 2013;24(6):e51-56. https:\/\/doi.org\/10.1016\/j.drugpo.2013.05.005.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"342_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000000555.","journal-title":"J Addict Med"},{"issue":"3","key":"342_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF03405066","volume":"94","author":"M Perreault","year":"2003","unstructured":"Perreault M, Rousseau M, Mercier C, et al. Accessibility to methadone substitution treatment: the role of a low-threshold program. Can J Public Health Rev Can Sante Publique. 2003;94(3):197\u2013200.","journal-title":"Can J Public Health Rev Can Sante Publique"},{"issue":"1","key":"342_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF03405382","volume":"98","author":"M Perreault","year":"2007","unstructured":"Perreault M, H\u00e9roux MC, White ND, Lauzon P, Mercier C, Rousseau M. Treatment retention and evolution of clientele in a low threshold methadone substitution treatment program in Montreal. Can J Public Health Rev Can Sante Publique. 2007;98(1):33\u20136.","journal-title":"Can J Public Health Rev Can Sante Publique"},{"issue":"5","key":"342_CR19","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2105\/ajph.91.5.774","volume":"91","author":"MW Langendam","year":"2001","unstructured":"Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001;91(5):774\u201380. https:\/\/doi.org\/10.2105\/ajph.91.5.774.","journal-title":"Am J Public Health"},{"key":"342_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drugalcdep.2015.08.037","volume":"156","author":"S Nolan","year":"2015","unstructured":"Nolan S, Hyashi K, Milloy MJ, et al. The impact of low-threshold methadone maintenance treatment on mortality in a canadian settiNG. Drug Alcohol Depend. 2015;156:57\u201361. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.08.037.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"342_CR21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1521\/aeap.2007.19.2.124","volume":"19","author":"P Millson","year":"2007","unstructured":"Millson P, Challacombe L, Villeneuve PJ, et al. Reduction in injection-related HIV risk after 6\u00a0months in a low-threshold methadone treatment program. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 2007;19(2):124\u201336. https:\/\/doi.org\/10.1521\/aeap.2007.19.2.124.","journal-title":"AIDS Educ Prev Off Publ Int Soc AIDS Educ"},{"issue":"3","key":"342_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/10550887.2012.694603","volume":"31","author":"S Stancliff","year":"2012","unstructured":"Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine\/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278\u201387. https:\/\/doi.org\/10.1080\/10550887.2012.694603.","journal-title":"J Addict Dis"},{"key":"342_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","volume":"103","author":"N Krawczyk","year":"2019","unstructured":"Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. J Subst Abuse Treat. 2019;103:1\u20138. https:\/\/doi.org\/10.1016\/j.jsat.2019.05.002.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"342_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/08897077.2019.1635557","volume":"41","author":"JE Hood","year":"2020","unstructured":"Hood JE, Banta-Green CJ, Duchin JS, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from seattle. Washington Subst Abuse. 2020;41(3):356\u201364. https:\/\/doi.org\/10.1080\/08897077.2019.1635557.","journal-title":"Washington Subst Abuse"},{"issue":"1","key":"342_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13722-019-0149-1","volume":"14","author":"J Carter","year":"2019","unstructured":"Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019;14(1):20. https:\/\/doi.org\/10.1186\/s13722-019-0149-1.","journal-title":"Addict Sci Clin Pract"},{"key":"342_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108444","volume":"131","author":"BM Buchheit","year":"2021","unstructured":"Buchheit BM, Wheelock H, Lee A, Brandt K, Gregg J. Low-barrier buprenorphine during the COVID-19 pandemic: a rapid transition to on-demand telemedicine with wide-ranging effects. J Subst Abuse Treat. 2021;131: 108444. https:\/\/doi.org\/10.1016\/j.jsat.2021.108444.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"342_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/ajad.13055","volume":"29","author":"T Iheanacho","year":"2020","unstructured":"Iheanacho T, Payne K, Tsai J. Mobile, community-based buprenorphine treatment for veterans experiencing homelessness with opioid use disorder: a pilot. Feasibility Study Am J Addict. 2020;29(6):485\u201391. https:\/\/doi.org\/10.1111\/ajad.13055.","journal-title":"Feasibility Study Am J Addict"},{"issue":"1","key":"342_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1370\/afm.2636","volume":"19","author":"P Leo","year":"2021","unstructured":"Leo P, Gastala N, Fleurimont J, et al. A community partnership to improve access to buprenorphine in a homeless population. Ann Fam Med. 2021;19(1):85. https:\/\/doi.org\/10.1370\/afm.2636.","journal-title":"Ann Fam Med"},{"issue":"5","key":"342_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/ADM.0000000000000774","volume":"15","author":"CD Nordeck","year":"2021","unstructured":"Nordeck CD, Buresh M, Krawczyk N, Fingerhood M, Agus D. Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic. J Addict Med. 2021;15(5):364\u20139. https:\/\/doi.org\/10.1097\/ADM.0000000000000774.","journal-title":"J Addict Med"},{"key":"342_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108641","volume":"135","author":"CO Cunningham","year":"2022","unstructured":"Cunningham CO, Khalid L, Deng Y, et al. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. J Subst Abuse Treat. 2022;135: 108641. https:\/\/doi.org\/10.1016\/j.jsat.2021.108641.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"342_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1089\/tmj.2021.0308","volume":"28","author":"AG Guillen","year":"2022","unstructured":"Guillen AG, Reddy M, Saadat S, Chakravarthy B. Utilization of telehealth solutions for patients with opioid use disorder using buprenorphine: a scoping review. Telemed J E-Health Off J Am Telemed Assoc. 2022;28(6):761\u20137. https:\/\/doi.org\/10.1089\/tmj.2021.0308.","journal-title":"Telemed J E-Health Off J Am Telemed Assoc"},{"issue":"1","key":"342_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1802741","volume":"379","author":"SE Wakeman","year":"2018","unstructured":"Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis\u2014buprenorphine myths and realities. N Engl J Med. 2018;379(1):1\u20134. https:\/\/doi.org\/10.1056\/NEJMp1802741.","journal-title":"N Engl J Med"},{"issue":"4","key":"342_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/ADM.0b013e31829727b2","volume":"7","author":"CO Cunningham","year":"2013","unstructured":"Cunningham CO, Roose RJ, Starrels JL, Giovanniello A, Sohler NL. Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. J Addict Med. 2013;7(4):287\u201393. https:\/\/doi.org\/10.1097\/ADM.0b013e31829727b2.","journal-title":"J Addict Med"},{"issue":"4","key":"342_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1521-0391.2013.12032.x","volume":"22","author":"CO Cunningham","year":"2013","unstructured":"Cunningham CO, Giovanniello A, Kunins HV, Roose RJ, Fox AD, Sohler NL. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. Am J Addict Am Acad Psychiatr Alcohol Addict. 2013;22(4):352\u20137. https:\/\/doi.org\/10.1111\/j.1521-0391.2013.12032.x.","journal-title":"Am J Addict Am Acad Psychiatr Alcohol Addict"},{"issue":"4","key":"342_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/ADM.0000000000000486","volume":"13","author":"SE Wakeman","year":"2019","unstructured":"Wakeman SE, Chang Y, Regan S, et al. Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence. J Addict Med. 2019;13(4):253\u20137. https:\/\/doi.org\/10.1097\/ADM.0000000000000486.","journal-title":"J Addict Med"},{"issue":"1","key":"342_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22\u201335. https:\/\/doi.org\/10.1080\/10550887.2016.1100960.","journal-title":"J Addict Dis"},{"issue":"1\u20132","key":"342_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.drugalcdep.2012.12.008","volume":"131","author":"MS Haddad","year":"2013","unstructured":"Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013;131(1\u20132):127\u201335. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.12.008.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"342_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2105\/AJPH.2019.305525","volume":"110","author":"LC Weinstein","year":"2020","unstructured":"Weinstein LC, Iqbal Q, Cunningham A, et al. Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: pennsylvania, 2017\u20132018. Am J Public Health. 2020;110(4):580\u20136. https:\/\/doi.org\/10.2105\/AJPH.2019.305525.","journal-title":"Am J Public Health"},{"key":"342_CR39","unstructured":"Tolbert J, Orgera K, Damico A. Key Facts about the Uninsured Population. Kaiser Family Foundation. Published November 6, 2020. https:\/\/www.kff.org\/uninsured\/issue-brief\/key-facts-about-the-uninsured-population\/ Accessed 13 Dec 2021."},{"issue":"12","key":"342_CR40","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1007\/s11606-021-06904-4","volume":"36","author":"JL Taylor","year":"2021","unstructured":"Taylor JL, Johnson S, Cruz R, Gray JR, Schiff D, Bagley SM. Integrating harm reduction into outpatient opioid use disorder treatment settings. J Gen Intern Med. 2021;36(12):3810\u20139. https:\/\/doi.org\/10.1007\/s11606-021-06904-4.","journal-title":"J Gen Intern Med"},{"key":"342_CR41","doi-asserted-by":"publisher","first-page":"108140","DOI":"10.1016\/j.jsat.2020.108140","volume":"119","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Lu T, DiRenno F, et al. Same-day vs delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program. J Subst Abuse Treat. 2020;119:108140. https:\/\/doi.org\/10.1016\/j.jsat.2020.108140.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"342_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ajad.12925","volume":"28","author":"CS Lee","year":"2019","unstructured":"Lee CS, Rosales R, Stein MD, et al. Brief report: low-barrier buprenorphine initiation predicts treatment retention among latinx and non-latinx primary care patients. Am J Addict. 2019;28(5):409\u201312. https:\/\/doi.org\/10.1111\/ajad.12925.","journal-title":"Am J Addict"},{"issue":"1","key":"342_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","volume":"15","author":"B Chan","year":"2021","unstructured":"Chan B, Gean E, Arkhipova-Jenkins I, et al. Retention strategies for medications for opioid use disorder in adults: a rapid evidence review. J Addict Med. 2021;15(1):74\u201384. https:\/\/doi.org\/10.1097\/ADM.0000000000000739.","journal-title":"J Addict Med"},{"key":"342_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108923","volume":"228","author":"JJ Wyse","year":"2021","unstructured":"Wyse JJ, Morasco BJ, Dougherty J, et al. Adjunct interventions to standard medical management of buprenorphine in outpatient settings: a systematic review of the evidence. Drug Alcohol Depend. 2021;228: 108923. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108923.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"342_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/10550887.2011.642758","volume":"31","author":"A Fareed","year":"2012","unstructured":"Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8\u201318. https:\/\/doi.org\/10.1080\/10550887.2011.642758.","journal-title":"J Addict Dis"},{"issue":"3","key":"342_CR46","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","volume":"46","author":"J Gryczynski","year":"2014","unstructured":"Gryczynski J, Mitchell SG, Jaffe JH, O\u2019Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients\u2019 reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356\u201361. https:\/\/doi.org\/10.1016\/j.jsat.2013.10.004.","journal-title":"J Subst Abuse Treat"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00342-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00342-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00342-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T18:06:34Z","timestamp":1667671594000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00342-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00342-1","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"19 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Duke University School of Medicine Institutional Review Board (Reference Number 0000\u20130003-0670\u20130211).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No authors have conflicts of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}